EGFR and non-small cell lung carcinoma: EGFR mutations located at the tyrosine kinase domain, sensitizes NSCLC to treatment with anti‐EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib.3, 4, 5, 6